Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SVK study of Sevikar in Chinese adults with essential hypertension
ChiCTR1900026574Phase 4Completed
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of olmesartan medoxomil + amlodipine in essential hypertension, sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Change in diastolic blood pressure at week 8. Started Nov 2020; status: completed.
02
Drugs
olmesartan medoxomil + amlodipine
03
Conditions
essential hypertension
Beyond the preview
Go deeper on ChiCTR1900026574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900026574.